C16 Glucosylceramide-d3 is intended for use as an internal standard for the quantification of C16 glucosylceramide by GC- or LC-MS. C16 glucosylceramide is an endogenous bioactive sphingolipid.1,2 It is a precursor in the synthesis of C16 lactosylceramide that is formed via metabolism of C16 ceramide by glucosylceramide synthase.3 Inhalation of C16 glucosylceramide reduces lung colonization by P. aeruginosa and increases survival in a mouse model of cystic fibrosis.1 C16 Glucosylceramide levels are elevated in the plasma of Parkinson's disease patients with cognitive impairments.2 [Matreya, LLC. Catalog No. 1533]
1.Kovacic, B., Sehl, C., Wilker, B., et al.Glucosylceramide critically contributes to the host defense of cystic fibrosis lungsCell Physiol. Biochem.41(3)1208-1218(2017) 2.Mielke, M.M., Maetzler, W., Haughey, N.J., et al.Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: A pilot studyPLoS One8(9)e73094(2013) 3.Holland, W.L., and Summers, S.A.Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolismEndocr. Rev.29(4)381-402(2008)